Latest news with #T-cell
Business Wire
3 days ago
- Health
- Business Wire
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030
CHICAGO--(BUSINESS WIRE)--Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. The CAR T Vision is for every eligible patient to have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. 'Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,' said Miguel Perales, MD, Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center (MSK); Past President, American Society for Transplantation and Cellular Therapy (ASTCT); and Co-Chair, CAR T Vision Steering Committee. 'When it comes to treating these potentially deadly cancers, every minute counts. That is why we established CAR T Vision with recommendations for interventions that, when adopted and scaled, will help many more eligible patients get the opportunity for cure within the next five years.' The roadmap report, developed by an independent Steering Committee comprised of leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts, provides the foundations for advocacy and action by local stakeholders to address the specific access challenges patients face in different geographies. Building on the report, expert Working Groups will be established to translate the Vision into concrete, measurable actions, including specific recommendations and a measurement framework to track progress. 'Limited awareness of CAR T-cell therapy, low referrals, hospital capacity challenges, and funding and reimbursement are among the barriers that either prevent people from accessing CAR T-cell therapy altogether or cause delays that advance a patient's cancer beyond the point of treatment eligibility. In short, these barriers cost lives,' said Anna Sureda, MD, PhD, Clinical Hematologist, Professor and Cell Therapy Researcher; and Co-Chair, CAR T Vision Steering Committee. 'We call on every stakeholder and organization with the ability to help shape better patient outcomes—policymakers, health system leaders, payors, healthcare providers, patient advocates, and industry—to join the growing coalition of Vision endorsers and help ensure every eligible patient has the opportunity for cure with CAR T-cell therapy.' Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report and join the coalition, visit About CAR T-cell therapy and CAR T Vision CAR T-cell therapy involves engineering a person's own immune cells to target and treat cancer and is currently approved for certain types of aggressive blood cancers, enabling some patients to remain cancer free for more than five years. 4,5,6,7 The CAR T Vision is for every eligible patient to have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. The CAR T Vision Steering Committee includes leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts. The new roadmap report details the challenges CAR T Vision aims to resolve through multidisciplinary collaboration and the urgent actions needed to make the Vision a reality. The report and initial activities of the CAR T Vision Steering Committee have been funded by Gilead Sciences and Kite, as the inaugural supporter of CAR T Vision. Report content has been reviewed by Gilead Sciences and Kite. However, the Steering Committee has editorial control of the CAR T Vision and its outputs, including the report. Dr. Perales has financial interests related to Gilead Sciences and Kite. To learn more about CAR T Vision, review the report and join the growing coalition of endorsers, visit 1 Kaltwasser J. Investigators set sights on optimizing CAR T-cell therapy in lymphoma. OncLive. 2022. Available online: 2 Chuhara, D, Liao, L, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023, September 21. 3 Canales Albendea MÁ, Canonico PL, Cartron G, et al. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med (Lausanne). 4 Abramson J, Palomba ML, Gordon LI, et al. Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 2024;144(1):3125. 5 Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. PMID: 36821768; PMCID: PMC10646788. 6 Rives S, Maude S, Hiramatsu H et al. S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY. HemaSphere 6():p 13-14, June 2022. | DOI: 10.1097/ 7 Xu J, Wang BY, Yu SH, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024 Apr 24;17(1):23. doi: 10.1186/s13045-024-01530-z. PMID: 38659046; PMCID: PMC11040812.
Yahoo
30-04-2025
- Health
- Yahoo
New vaccine to treat 15 types of cancer now available on NHS
A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease. Patients will be able to receive the immunotherapy in a vaccine, called nivolumab, in a treatment that will take just 15 minutes rather than spending an hour on an IV drip. Around 1,200 patients a month will receive it for 15 different types of cancer, including skin, bladder and oesophageal cancer as England becomes the first country in Europe to offer it. The drug is a monoclonal antibody that works by clinging to a protein called PD-1 on an immune cell called T-cell. It works by blocking cancer cells from switching off T-cells, allowing the immune system to seek out and destroy cancer cells. NHS England said the jab, being rolled out to eligible patients next month, would save around 1,000 hours of treatment time for patients and clinicians every month. Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This treatment is used for 15 different types of the disease, so it will free up thousands of valuable clinicians' time every year, allowing teams to treat even more patients and helping hospital capacity. 'And this is just the latest development in the NHS's ongoing commitment to provide patients with the latest cancer therapies and treatment options that truly transform lives.' Minister for Public Health and Prevention, Ashley Dalton, said: "Britain is a hotbed of innovation, masterminding the newest tech and medical inventions to help people navigate illness. A new jab that fastens up cancer treatment is a prime example of this, so it's fantastic to see that cancer patients in England will be among the first in Europe to benefit.' "With cancer medicines getting better all the time, this government will ensure that NHS patients are among the first to access the latest treatments and technology.' And James Richardson, Clinical Pharmacist and National Specialty Adviser for Cancer Drugs, said: 'I am delighted that NHS patients across England will soon be able to benefit from this quicker-to-administer, effective treatment, that can be used to treat a range of cancer types, including skin cancer and solid tumours originating in the kidneys. 'This is a significant advancement in cancer treatment, with the potential to improve the lives of thousands of patients each month.'
The Independent
30-04-2025
- Health
- The Independent
New vaccine to treat 15 types of cancer now available on NHS
A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease. Patients will be able to receive the immunotherapy in a vaccine, called nivolumab, in a treatment that will take just 15 minutes rather than spending an hour on an IV drip. Around 1,200 patients a month will receive it for 15 different types of cancer, including skin cancer, bladder as England becomes the first country in Europe to offer it. The drug is a monoclonal antibody that works by clinging to a protein called PD-1 on an immune cell called T-cell. It works by blocking cancer cells from switching off T-cells, allowing the immune system to seek out and destroy cancer cells. NHS England said the jab, being rolled out to eligible patients next month, would save around 1,000 hours of treatment time for patients and clinicians every month. Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This treatment is used for 15 different types of the disease, so it will free up thousands of valuable clinicians' time every year, allowing teams to treat even more patients and helping hospital capacity. 'And this is just the latest development in the NHS's ongoing commitment to provide patients with the latest cancer therapies and treatment options that truly transform lives.' Minister for Public Health and Prevention, Ashley Dalton, said: "Britain is a hotbed of innovation, masterminding the newest tech and medical inventions to help people navigate illness. A new jab that fastens up cancer treatment is a prime example of this, so it's fantastic to see that cancer patients in England will be among the first in Europe to benefit.' "With cancer medicines getting better all the time, this government will ensure that NHS patients are among the first to access the latest treatments and technology.' And James Richardson, Clinical Pharmacist and National Specialty Adviser for Cancer Drugs, said: 'I am delighted that NHS patients across England will soon be able to benefit from this quicker-to-administer, effective treatment, that can be used to treat a range of cancer types, including skin cancer and solid tumours originating in the kidneys. 'This is a significant advancement in cancer treatment, with the potential to improve the lives of thousands of patients each month.'
The Independent
30-04-2025
- Health
- The Independent
NHS becomes first health service in Europe to offer new cancer jab
Thousands of cancer patients every year will be able to receive a quick and easy injection instead of a drip as England becomes the first country in Europe to offer a new jab. The NHS is rolling out an injectable form of the immunotherapy nivolumab, which can be given in three to five minutes and works for 15 different cancers, such as lung, bowel, kidney, bladder, oesophageal, skin and head and neck cancer. The Medicines and Healthcare products Regulatory Agency (MHRA) approved the new under-the-skin injection version of nivolumab, also known as Opdivo, on Wednesday as an alternative to intravenous (IV) infusions. At present, patients need to be in hospital for a 30 or 60-minute infusion every two to four weeks. Under the change, patients will still go to hospital but the jab will be administered in just a few minutes. NHS England said the roll-out will save more than a year's worth of treatment time for patients and NHS teams every year, freeing up staff for more appointments and making care swifter for patients. Nivolumab is a monoclonal antibody that works by binding to a protein called PD-1 on a type of immune cell called T-cell. This blocks cancer cells from switching off T-cells, allowing the immune system to seek out and destroy cancer cells. It is estimated around 1,200 patients in England per month could benefit from the switch – around two in five patients who currently receive IV nivolumab. Most new patients are also likely to start treatment with nivolumab injections. Professor Peter Johnson, NHS England national clinical director for cancer, said: ' Immunotherapy has already been a huge step forward for many NHS patients with cancer, and being able to offer it as an injection in minutes means we can make the process far more convenient. 'This treatment is used for 15 different types of the disease, so it will free up thousands of valuable clinicians' time every year, allowing teams to treat even more patients and helping hospital capacity. 'And this is just the latest development in the NHS's ongoing commitment to provide patients with the latest cancer therapies and treatment options that truly transform lives.' Minister for public health and prevention, Ashley Dalton, said: 'Britain is a hotbed of innovation, masterminding the newest tech and medical inventions to help people navigating illness. 'A new jab that fastens up cancer treatment is a prime example of this, so it's fantastic to see cancer patients in England will be among the first in Europe to benefit. 'With cancer medicines getting better all the time, this Government will ensure that NHS patients are among the first to access the latest treatments and technology. 'Our National Cancer Plan will transform the way we approach this disease, improving care and bringing this country's cancer survival rates back up to the standards of the best in the world.' The new treatment comes at no extra cost to the NHS after an agreement was reached between NHS England and the manufacturer Bristol Myers Squibb.
